TELA Bio Inc

TELA USD0.001
Create an alert
Sell$0.63
Buy$0.68
$0.01 (1.19%)
Last updated today at
Back to dashboard

Company Information

About this company

TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.

Key people

Jeffrey Blizard
President
Paul G. Thomas
Independent Director
Heather C. Getz
Chief Executive Officer, Principal Executive Officer, Director
Roberto E. Cuca
Chief Financial Officer, Chief Operating Officer, Corporate Secretary
Paul Talmo
Chief Technology Officer
Greg Firestone
Chief Business Officer
Guido J. Neels
Independent Director
Guy Paul Nohra
Independent Director
William Plovanic
Independent Director
Betty Jo Rocchio
Independent Director
Click to see more

Key facts

  • Shares in issue
    44.89m
  • EPIC
    TELA
  • ISIN
    US8723811084
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Medical Equipment & Supplies
  • Market cap
    $29.02m
  • Employees
    150
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.